We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
Biovian, a biopharmaceutical CDMO providing One-Stop-Shop GMP services to a global client base, is delighted to announce the appointment of Jayme Tortorici, based in San Diego, CA, as its new Business Development Director. Jayme Tortorici …
We are delighted to tell you that Biovian will be participating in the Biotech Week Boston on September 18-21, 2023! You can meet our team at the concurrent BPI/Cell & Gene Therapy Manufacturing & Commercialization …
Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland. The new facility will cover an …
We are thrilled to announce that Biovian will be participating in the 15th Annual Bioprocessing Summit in Boston, scheduled to take place from August 14-17, 2023. This premier event brings together industry leaders and experts …
Biovian is gearing up to exhibit at the highly anticipated BIO International Convention in June 5-8, 2023. This premier global event will bring together pioneers, innovators, and thought leaders from around the world to explore …
Biovian will be exhibiting at the 26th Annual ASGCT Meeting held in Los Angeles, in May 16-20, 2023. Meet the Biovian representatives Magnus Gustafsson CBO, Eero Mustalahti Head of Business Development and Taru Värri Marketing …
According to the Merriam-Webster Dictionary, the English noun “solution” refers to: i) an action or process of solving a problem, ii) a bringing or coming to an end or into a state of discontinuity, iii) …
Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed …
We are delighted to welcome Dr. Uwe Gottschalk to Biovian’s Board of Directors. “At Keensight, we are very pleased to welcome Uwe to the Board of Biovian” said Dr. Pierre Remy, Chairman of the Board. …
Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
Biovian, a Finnish Contract Development and Manufacturing Organization, CDMO, has year after year received a high net promoter score, NPS. NPS measures customer satisfaction and loyalty by asking clients how likely they are to recommend …
ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101, followed by 200 L scale …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
What is the first thing that comes to your mind when you think about a warehouse? Maybe an image of a truck stacking pallets and boxes in a giant hall? However, the warehouse at Biovian …
What does a project manager do and what is needed to be successful in such a position? The job title has a broad meaning and job descriptions for project managers vary greatly. Even within the …
Biovian Oy announces that its Board of Directors has named Antti Nieminen, as a Chief Executive Officer, effective January 1st, 2022. Nieminen succeeds Co-Founder Dr. Knut Ringbom, who will transition to Senior Advisor of Biovian, …
Biovian’s client satisfaction survey was conducted in November using Net Promoter Score (NPS) survey. The score of 67 puts Biovian into the category “Excellent” based on the creators of NPS, Bain & Co. Flexibility, good …
New Horizons 2021 event took place on December 9th in Stockholm. Dr. Magnus Gustafsson from Biovian gave a talk about “Gene therapy today and tomorrow.” New Horizons is an international educational forum that focuses on …
Biovian received a new automated filling line right before Christmas in 2020 from Optima packaging group. This article describes the project from the planning phase until the assembly of the filling line. The project is …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …
GEN, one of the biggest magazines in the field of genetic engineering and biotechnology, discussed with four experts how the relationship between a CDMO and a technology provider can accelerate the transition from academia to …
Here we present some basic concepts of Viral Vectors used in gene therapy applications with special focus on AAV and Adenovirus vectors. Please proceed to this page if you are looking for information about our …
Announcements about job openings have been frequent at Biovian, since the company is growing steadily. Thus, several persons have been hired during the last few months. We asked Eija Martikkala, one of our newest colleagues, …
Tenboron Ltd, the developer of a novel boron carrier for use in Boron Neutron Capture Therapy (BNCT), has selected Biovian Oy as a CDMO partner for GMP manufacturing of their drug candidate for phase I …
The whys and the whats of GMP production of biopharmaceuticals. Why’d you have to go and make things so complicated? This chorus of the pop-rock song, Complicated, may reflect the thoughts of drug developers when …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Eurocine Vaccines AB announces the completion of knowledge transfer and preparations for the development of the manufacturing process for the company´s chlamydia vaccine candidate. The process development activities initiated at Biovian according to schedule, are …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
The article discusses the challenges small and mid-sized companies are facing when taking AAV vector-based innovations from the laboratory bench to the clinic. While in-house manufacturing may be an option for some companies, partnering with a …
Adenoviruses are among the most attractive Viral Vectors for gene therapy because of their well-defined biology and characteristics. They have a high packaging capacity and can accommodate large transgene inserts of sizes up to ~8 kb. Adenovirus vectors also have high transduction efficiency and they can infect both dividing and non-dividing cells in a broad range of cell and tissue …
Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
